- Home
- OMGA
as 12-18-2024 9:56am EST
Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using epigenomic controllers, Omega is seeking to transform the practice of human medicine through selective and direct control of the human genome to treat and cure disease. It operates in the U.S.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 53.6M | IPO Year: | 2021 |
| Target Price: | $9.20 | AVG Volume (30 days): | 273.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.33 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.75 - $6.30 | Next Earning Date: | 11-14-2024 |
| Revenue: | $8,095,000 | Revenue Growth: | 185.04% |
| Revenue Growth (this year): | 181.29% | Revenue Growth (next year): | -40.72% |
Latest Omega Therapeutics Inc. News
OMGA Breaking Stock News: Dive into OMGA Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
Omega Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS In Line
MT Newswires
a month ago
Raymond James Downgrades Omega Therapeutics to Market Perform From Outperform
Zacks
a month ago
Omega Therapeutics, Inc. (OMGA) Reports Q3 Loss, Tops Revenue Estimates
GlobeNewswire
a month ago
Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results
Zacks
2 months ago
Oculis Holding AG (OCS) Moves 7.9% Higher: Will This Strength Last?
PR Newswire
2 months ago
Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence
GlobeNewswire
2 months ago
Omega Therapeutics to Present Multiple Posters Highlighting Versatile Platform Capabilities at Upcoming Scientific Meetings
PR Newswire
3 months ago
Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors
Compare OMGA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OMGA Omega Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.